Vimarsana
Biggest News Aggregation in the World

Page 4 - Last Accessed News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Last Accessed. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Last Accessed Today - Breaking & Trending Today

Metadata Remixed | Association of Certified E-Discovery Specialists (ACEDS) - Vimarsana News

Metadata Remixed | Association of Certified E-Discovery Specialists (ACEDS)

Metadata: the data about the data, the extra goodies, the secret bits that tell you the when, where, and how of a file. Everyone who has used eDiscovery for a while knows some metadata...

ADB's "just transition" harming waste pickers and the environment - Vimarsana News

ADB's "just transition" harming waste pickers and the environment

No More Excuses, ADB! Prioritize Sustainable Solutions and Stop Funding Harmful Waste-to-Energy (WtE) Incinerators 02 May 2023 -  The Asian Development

Bimekizumab Phase 3 Data in Hidradenitis Suppurativa Show Clinically Meaningful, Deep and Maintained Response over 48 Weeks - Vimarsana News

Bimekizumab Phase 3 Data in Hidradenitis Suppurativa Show Clinically Meaningful, Deep and Maintained Response over 48 Weeks

Patients treated with investigational bimekizumab, an IL-17A and IL-17F inhibitor, achieved statistically significant and clinically meaningful improvements...

Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial Spondyloarthritis - Vimarsana News

Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial Spondyloarthritis

/PRNewswire/ -- UCB, a global biopharmaceutical company, today announced that Annals of the Rheumatic Diseases has published 24-week results from the Phase 3...

Kyowa Kirin Co., Ltd.: Kyowa Kirin Receives European Commission Approval for Use of CRYSVITA?(burosumab) for the Treatment of Tumour-Induced Osteomalacia (TIO) - Vimarsana News

Kyowa Kirin Co., Ltd.: Kyowa Kirin Receives European Commission Approval for Use of CRYSVITA?(burosumab) for the Treatment of Tumour-Induced Osteomalacia (TIO)

CRYSVITA is the first approved biologic treatment in the EU for patients with TIO who cannot undergo surgical removal of tumours Kyowa Kirin Co., Ltd. (TSE: 4151, Kyowa Kirin) today announced that